A Phase 1 interventional study of Nintedanib and Docetaxel in Carcinoma, Non-Small-Cell Lung, sponsored by Boehringer Ingelheim. Completed at 6 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2025-02-11.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung — 1 open to participants now, 2 under way, none of them phase 3. nintedanib · Carcinoma, Non-Small-Cell Lung.
Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, this one is the 13th largest by enrollment, is one of 3 that started in 2014, is one of 9 in phase 1, and was the 13th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →1 of the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung is open now, in 1 country. Recruiting first, the newest first:
China Medical University Hospital · Sites in Taiwan
Ages 20–70
By country, each count listing its studies:
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 7 · Phase 3 3
First in 2005; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 16 across the 19 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 8 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim: 3 open now, 5 under way, 1 of them phase 3. Of 60 finished, 53 (88%) have results posted.
Among the 68 studies in Carcinoma, Non-Small-Cell Lung by Boehringer Ingelheim, this one is the 44th largest by enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2014, is one of 21 in phase 1, and was the 41st registered.
Boehringer Ingelheim’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing nintedanib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Boehringer Ingelheim’s 68 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
To determine the appropriateness of the dose of nintedanib 200 mg b.i.d. plus docetaxel 75 mg/m2 as starting dose by evaluating the safety in Japanese patients with body surface area (BSA) \<1.5 m2 and locally advanced or metastatic adenocarcinoma subtype non-small cell lung cancer (NSCLC) after failure of first line platinum- based chemotherapy
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
further exclusion criteria may be applied
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
patients to receive backbone chemotherapy and nintedanib
Drug: Nintedanib · Drug: Docetaxel
Nintedanib
Docetaxel
Number of Patients Experiencing Dose Limiting Toxicity (DLT) in Cycle 1
DLT was defined as any of the following study drug related adverse events (AEs): * Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 non-haematological toxicity except transient electrolyte abnormality and isolated increase of gamma-glutamyltransferase (GGT); gastrointestinal toxicity, despite adequate supportive care * CTCAE grade 4 haematological toxicity; Neutrophil count decreased or white blood cell count (not associated with fever) for \>7 days despite adequate supportive treatment * CTCAE grade 4 febrile neutropenia with fever ≥38.5 degrees * CTCAE grade ≥2 alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) increase in conjunction with CTCAE grade ≥2 total bilirubin increase * Inability to resume nintedanib dosing within 14 days after stopping Investigators judged clinically as DLT after dose reduction and severity medically notable (CTCAE, version 3). Sponsor with safety review committee was allowed to confirm the adequacy of this judgment.
Time frame: Cycle 1, from first administration of study medication up to 21 days thereafter.
Maximum Measured Concentration (Cmax) of Nintedanib
This outcome measure presents the maximum measured concentration (Cmax) of nintedanib in plasma in cycle 1.
Time frame: At 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 h after first drug administration of docetaxel in cycle 1.
Cmax of Docetaxel
This outcome measure presents the Cmax of docetaxel in plasma in cycles 1 and 2.
Time frame: just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)
Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 to Time of the Last Quantifiable Concentration (AUC0-tz)
This outcome measure presents the area under the concentration-time curve of nintedanib over the time interval from 0 to time of the last quantifiable concentration in plasma (AUC0-tz) in cycle 1.
Time frame: At 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 after first drug administration of docetaxel in cycle 1.
AUC0-tz of Docetaxel
This outcome measure presents AUC0-tz of docetaxel in plasma in cycles 1 and 2.
Time frame: just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)
Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)
This outcome measure presents the Area under the concentration-time curve of nintedanib over the time interval from 0 extrapolated to infinity in plasma (AUC0-infinity) in cycle 1.
Time frame: at 23:55 hours (h) after the first dose of docetaxel (which is 5 minutes prior to first dose of nintedanib) and at 25, 26, 27, 28, 30, 31, 34 and 47:55 h after first drug administration of docetaxel in cycle 1.
AUC0-infinity of Docetaxel
This outcome measure presents the AUC0-infinity of docetaxel in plasma in cycles 1 and 2.
Time frame: just before administration of docetaxel administration -0:05 hours (h), at the end of infusion (1:00), and at timepoints after the first dose of docetaxel 1:30 h, 2, 3, 4, 7, 23:55, 47:55 h in cycle 1 and 2 (if administered)
This is a single arm study but it was allowed to discontinue the docetaxel treatment and continue the nintedanib treatment.
| Milestone | Nintedanib Plus Docetaxel (Patient Disposition for Nintedanib) | Nintedanib Plus Docetaxel (Patient Disposition for Docetaxel) |
|---|---|---|
| Started | 10 | 0 |
| Completed | 0 | 0 |
| Not completed | 10 | 0 |
| Withdrew: Progressive disease | 10 | 0 |
| Milestone | Nintedanib Plus Docetaxel (Patient Disposition for Nintedanib) | Nintedanib Plus Docetaxel (Patient Disposition for Docetaxel) |
|---|---|---|
| Started | 0 | 10 |
| Completed | 0 | 0 |
| Not completed | 0 | 10 |
| Withdrew: Progressive disease | 0 | 6 |
| Withdrew: Other adverse event | 0 | 4 |
DLT was defined as any of the following study drug related adverse events (AEs): * Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 non-haematological toxicity except transient electrolyte abnormality and isolated increase of gamma-glutamyltransferase (GGT); gastrointestinal toxicity, despite adequate supportive care * CTCAE grade 4 haematological toxicity; Neutrophil count decreased or white blood cell count (not associated with fever) for \>7 days despite adequate supportive treatment * CTCAE grade 4 febrile neutropenia with fever ≥38.5 degrees * CTCAE grade ≥2 alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) increase in conjunction with CTCAE grade ≥2 total bilirubin increase * Inability to resume nintedanib dosing within 14 days after stopping Investigators judged clinically as DLT after dose reduction and severity medically notable (CTCAE, version 3). Sponsor with safety review committee was allowed to confirm the adequacy of this judgment.
| Participants | Nintedanib Plus Docetaxel |
|---|---|
| Total with DLTs - all grades | 2 |
| Total with DLTs - grade 1/2 | 0 |
| Total with DLTs - grade 3/4/5 | 2 |
| Hepatobiliary disorders (hep. dis.) - all grades | 1 |
| Hep. dis. - grade 1/2 | 1 |
| Hep. dis. - grade 3/4/5 | 0 |
| Hep. dis. - hyperbilirubinaemia - all grades | 1 |
| Hep. dis. - hyperbilirubinaemia - grade 1/2 | 1 |
| Hep. dis. - hyperbilirubinaemia - grades 3/4/5 | 0 |
| Investigations (inv.) - all grades | 2 |
| Inv. - grade 1/2 | 0 |
| Inv. - grade 3/4/5 | 2 |
| Inv. - ALT increased - all grades | 2 |
| Inv. - ALT increased - grades 1/2 | 0 |
| Inv. - ALT increased - grades 3/4/5 | 2 |
| Inv. - AST increased - all grades | 2 |
| Inv. - AST increased - grades 1/2 | 0 |
| Inv. - AST increased - grades 3/4/5 | 2 |
This outcome measure presents the maximum measured concentration (Cmax) of nintedanib in plasma in cycle 1.
| nanogram (ng)/ millilitre (mL) | Nintedanib Plus Docetaxel |
|---|---|
| Maximum Measured Concentration (Cmax) of Nintedanib | 65.1 ± 86.6 |
This outcome measure presents the Cmax of docetaxel in plasma in cycles 1 and 2.
| nanogram (ng)/ millilitre (mL) | Nintedanib Plus Docetaxel |
|---|---|
| Cycle 1 | 2710 ± 37.6 |
| Cycle 2 | 2680 ± 49.6 |
This outcome measure presents the area under the concentration-time curve of nintedanib over the time interval from 0 to time of the last quantifiable concentration in plasma (AUC0-tz) in cycle 1.
| ng*h/mL | Nintedanib Plus Docetaxel |
|---|---|
| Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 to Time of the Last Quantifiable Concentration (AUC0-tz) | 342 ± 59.8 |
This outcome measure presents AUC0-tz of docetaxel in plasma in cycles 1 and 2.
| ng*h/mL | Nintedanib Plus Docetaxel |
|---|---|
| Cycle 1 | 3080 ± 27.4 |
| Cycle 2 | 3320 ± 29.8 |
This outcome measure presents the Area under the concentration-time curve of nintedanib over the time interval from 0 extrapolated to infinity in plasma (AUC0-infinity) in cycle 1.
| ng*h/mL | Nintedanib Plus Docetaxel |
|---|---|
| Area Under the Concentration-time Curve of Nintedanib Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) | 381 ± 62.7 |
This outcome measure presents the AUC0-infinity of docetaxel in plasma in cycles 1 and 2.
| ng*h/mL | Nintedanib Plus Docetaxel |
|---|---|
| Cycle 1 | 3320 ± 26.2 |
| Cycle 2 | 3590 ± 26.6 |
Collected over From the first administration of docetaxel up to 28 days after the day of the last administration of study medication (docetaxel and/or nintedanib) up to 1002 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nintedanib Plus Docetaxel | 0/10 (0%) | 6/10 (60%) | 10/10 (100%) |
| Event | Nintedanib Plus Docetaxel |
|---|---|
| Metastases to central nervous systemNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/10 |
| FatigueGeneral disorders | 1/10 |
| Metastases to meningesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/10 |
| Paraneoplastic pleural effusionRespiratory, thoracic and mediastinal disorders | 1/10 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/10 |
| Event | Nintedanib Plus Docetaxel |
|---|---|
| Neutrophil count decreasedInvestigations | 10/10 |
| White blood cell count decreasedInvestigations | 10/10 |
| AlopeciaSkin and subcutaneous tissue disorders | 9/10 |
| Alanine aminotransferase increasedInvestigations | 8/10 |
| Aspartate aminotransferase increasedInvestigations | 7/10 |
| ConstipationGastrointestinal disorders | 5/10 |
| DiarrhoeaGastrointestinal disorders | 5/10 |
| NauseaGastrointestinal disorders | 5/10 |
| FatigueGeneral disorders | 4/10 |
| Gamma-glutamyltransferase increasedInvestigations | 4/10 |
Treated set included all patients who were dispensed study medication and were documented to have taken at least one dose of study treatment (docetaxel or nintedanib).
| Age, Continuous(Years) | Nintedanib Plus Docetaxel |
|---|---|
| Mean | 67.30 ± 6.98 |
| Sex: Female, Male(Participants) | Nintedanib Plus Docetaxel |
|---|---|
| Female | 8 |
| Male | 2 |
| Ethnicity (NIH/OMB)(Participants) | Nintedanib Plus Docetaxel |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Nintedanib Plus Docetaxel |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 10 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
Plan to share: No — Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.mystudywindow.com/msw/datatransparency
Ran from Dec 2014 to primary completion in Jan 2016, 12 months.
Results were first posted in Aug 2018, 2 years 6 months after primary completion.
Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 12 months is below that.
Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nintedanib · Docetaxel
Carcinoma, Non-Small-Cell Lung →